← Leaderboards
Matthias Clauss
Indiana University Indianapolis
$8,411,925
Attributed
$12,471,857
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2008–23$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$12,471,857 · 8
By mechanism
R01$9,862,945 · 4
R44$1,673,916 · 1
R21$426,075 · 1
R41$281,155 · 1
R43$227,766 · 1
Top collaborators
- Irina Petrache6 shared
- Samir Kumar Gupta5 shared
- Natalia Bogatcheva1 shared
- Douglas W.P. Hay1 shared
- Christa Lynn Modery1 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Roland W. Herzog$25,146,618
- Michelle L Block$8,185,746
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsEndothelial CellsLeadProteinsInflammationProductionLinkMediatingCardiovascular DiseasesT-LymphocyteLaboratoriesIn VivoInflammatoryLiquid SubstanceMonocyteIn VitroMortality Vital StatisticsEndotheliumCytokinePathologyFunctional DisorderFutureHiv InfectionsApoptosis
Grant awards (24)
Potential Role of Extracellular Vesicles for the Development of HIV Comorbidities$588,778
R01 · FY2023 · HL · contact PI
Potential Role of Extracellular Vesicles for the Development of HIV Comorbidities$619,748
R01 · FY2022 · HL · contact PI
Potential Role of Extracellular Vesicles for the Development of HIV Comorbidities$619,748
R01 · FY2021 · HL · contact PI
Potential Role of Extracellular Vesicles for the Development of HIV Comorbidities$647,413
R01 · FY2020 · HL · contact PI
Development of a Fully Humanized Antibody for Treating Lung Emphysema$958,776
R44 · FY2018 · HL
HIV-Nef protein and endothelial dysfunction$441,141
R01 · FY2018 · HL · contact PI
Humanized EMAP II mAb as a Novel Therapy for Viral-Associated Lung Injury$281,155
R41 · FY2018 · HL · contact PI
Development of a Fully Humanized Antibody for Treating Lung Emphysema$715,140
R44 · FY2017 · HL
HIV-Nef protein and endothelial dysfunction$445,197
R01 · FY2017 · HL · contact PI
HIV-Nef protein and endothelial dysfunction$438,021
R01 · FY2016 · HL · contact PI
HIV-Nef protein and endothelial dysfunction$456,077
R01 · FY2015 · HL · contact PI
HIV-Nef protein is disseminated in blood cells and causes endothelial dysfunction$192,075
R21 · FY2015 · HL · contact PI
Development of a Fully Humanized Antibody for Treating Lung Emphysema$175,753
R43 · FY2015 · HL · contact PI
Development of a Fully Humanized Antibody for Treating Lung Emphysema$52,013
R43 · FY2015 · HL · contact PI
HIV-Nef protein is disseminated in blood cells and causes endothelial dysfunction$234,000
R21 · FY2014 · HL · contact PI
HIV, Inflammation, and Endothelial Dysfunction$744,909
R01 · FY2012 · HL
HIV, Inflammation, and Endothelial Dysfunction$771,965
R01 · FY2011 · HL
EMAP II, a molecular link of inflammation and apoptosis in pulmonary emphysema.$375,446
R01 · FY2011 · HL · contact PI
HIV, Inflammation, and Endothelial Dysfunction$878,381
R01 · FY2010 · HL
EMAP II, a molecular link of inflammation and apoptosis in pulmonary emphysema.$375,724
R01 · FY2010 · HL · contact PI
HIV, Inflammation, and Endothelial Dysfunction$900,940
R01 · FY2009 · HL
EMAP II, a molecular link of inflammation and apoptosis in pulmonary emphysema.$380,751
R01 · FY2009 · HL · contact PI
HIV, Inflammation, and Endothelial Dysfunction$809,906
R01 · FY2008 · HL
EMAP II, a molecular link of inflammation and apoptosis in pulmonary emphysema.$368,800
R01 · FY2008 · HL · contact PI